Naiyereh Alipour Eskandani

Dr. Naiyereh Alipour Eskandani

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2026 in Materials Today Bio
Verified
Journal Article
Open access
MTMahdi Navid Talemi
Mahdi Navid Talemi
Marzieh Ramezani FaraniMarzieh Ramezani Farani
Marzieh Ramezani Farani
NENaiyereh Alipour Eskandani
Naiyereh Alipour Eskandani
DMDanial Mirzaee
Danial Mirzaee
Iraj AlipourfardIraj Alipourfard
Iraj Alipourfard
YHYun Suk Huh
Yun Suk Huh
RNA therapeutics have come of age as clinically validated modalities including mRNA, siRNA, antisense oligonucleotides (ASOs), and in vivo genome editing, with lipid nanoparticles (LNPs) as the main non-viral delivery system. This review defines programmable LNPs as systems whose composition and interfacial chemistry are tuned to control organ tropism, cell specificity, intracellular trafficking, and immune interactions. We summarize design rules across four core components (ionizable lipid, phospholipid, cholesterol, PEG-lipid) and highlight levers like apparent pKa optimization (∼6–7 for hepatic delivery), biodegradable linkers, PEG-anchor-dependent shedding, ligands (e.g., GalNAc), and selective organ-targeting (SORT) lipids that redirect biodistribution beyond the liver. We survey advances in data-guided formulation, including DNA-barcoded in vivo libraries, machine learning, and physics-based prediction, plus scalable manufacturing (microfluidics, confined impinging-jet mixing, tangential-flow filtration) and Quality-by-Design with process-analytical technologies. A comprehensive characterization toolkit (size/ζ-potential, cryo-EM/SAXS, RNA encapsulation and integrity, apparent pKa, in vivo barcoding) maps to critical quality attributes. Applications span vaccines, protein replacement, siRNA/ASO delivery, and CRISPR platforms, with clinical examples like patisiran, COVID-19 and RSV mRNA vaccines, in-human transthyretin (TTR) editing, and individualized melanoma vaccination. We analyze translational constraints like endosomal escape, reactogenicity and anti-PEG immunity, complement activation, and lot-to-lot control, plus success factors: corona-aware design, dose-efficient potency at low lipid burden, redosing strategies, and fit-for-purpose biomarkers. Together, programmable LNPs offer a generalizable path to extrahepatic, cell-aware RNA medicine when coupled to rigorous analytics and platform manufacturing.

27 May 2026 in Molecular Biology Reports
Verified
Journal Article
Closed access
RKRasa Khosrofar
Rasa Khosrofar
PNParmida Nafei
Parmida Nafei
FZFarshad Zare
Farshad Zare
ASAmirhossein Sadrmohammadbagheri
Amirhossein Sadrmohammadbagheri
FZFaranak Zargari
Faranak Zargari
RSReza Akhavan Sigari
Reza Akhavan Sigari

19 September 2026 in Thyroid Research
Verified
Journal Article
Open access
PDF file
IMIman Morshedi
Iman Morshedi
NSNardin Sedghizadeh
Nardin Sedghizadeh
ZSZahra Safavi
Zahra Safavi
SDSeyednima Darboy
Seyednima Darboy
MDMohammadmahdi Doosti
Mohammadmahdi Doosti
ASAmr Ali Mohamed Abdelgawwad El Sehrawy
Amr Ali Mohamed Abdelgawwad El Sehrawy
Thyroid cancer incidence has risen sharply in recent decades, yet the mechanisms underlying tumor development and progression remain incompletely understoo

1 August 2026 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
JVJalalova Vazira
Jalalova Vazira
BBBekzod Babamuratov
Bekzod Babamuratov
LALola Abduraximova
Lola Abduraximova
ISI.B. Sapaev
I.B. Sapaev
SBSapaev Bayramdurdi
Sapaev Bayramdurdi
INIbodullayev Hayitali Normurotovich
Ibodullayev Hayitali Normurotovich